Moreover, the noncanonical route of GLI activation has been frequently reported in many other solid tumors, such as NSCLC, PDAC, gastric adenocarcinomas, and triple-negative breast cancer, leading to SMO inhibitor resistance. This evidence concerns the gene GLI1 and non-small cell lung carcinoma.